Drug Overview

Suratadenoturev is a modern and sophisticated cancer treatment that represents the next generation of biological medicine. It is an oncolytic virus, which means it is a virus that has been specifically engineered in a laboratory to find and destroy cancer cells while leaving healthy cells alone. In the medical community, it is highly regarded as a “Smart Drug” because it possesses both “Immunotherapy” and “Targeted Therapy” characteristics.

This medication acts like a heat-seeking missile. It travels through the body to locate tumors and then works from the inside out to break them apart. For patients and doctors, it offers a way to treat aggressive cancers that may not have responded to traditional chemotherapy or radiation.

• Generic name: Suratadenoturev (also known as OBP-301 or Telomelysin)
• US Brand names: None (Currently an investigational drug)
• Drug Class: Oncolytic Virus; Gene Therapy; Immunotherapy
• Route of Administration: Intratumoral injection (injected directly into the tumor)
• FDA Approval Status: Investigational (Currently in clinical trials; has received Orphan Drug and Fast Track designations for specific uses)

What Is It and How Does It Work? (Mechanism of Action)

Suratadenoturev is a modified version of the adenovirus, which is a common virus that usually causes the cold. To turn it into a cancer-fighting tool, scientists changed its genetic code so it can only grow inside cancer cells.

At the molecular level, the drug works through a three-step process:

1. Selective Entry and Replication: The virus is designed to target an enzyme called telomerase. Healthy cells usually have very little telomerase, but cancer cells have a lot of it because they use it to live forever. Suratadenoturev only turns “on” when it detects high levels of telomerase. Once inside a cancer cell, the virus begins to make thousands of copies of itself.
2. Oncolysis (Cell Bursting): As the virus copies multiply, the cancer cell becomes physically overstuffed. Eventually, the cell membrane weakens and the cancer cell bursts. This process is called “oncolysis.”
3. Immune Activation: When the cancer cell bursts, it releases “tumor antigens” and signaling molecules into the body. This acts like a giant alarm for the immune system. The body’s natural T-cells are then trained to recognize these specific cancer markers. This turns the tumor into its own vaccine, teaching the immune system to find and kill cancer cells that have spread elsewhere in the body.

FDA Approved Clinical Indications

As an investigational agent, suratadenoturev does not have official FDA approval for standard medical use yet. However, it is being used in international clinical trials for several conditions.

Oncological uses

• Investigational treatment for Esophageal Cancer (often combined with radiation).
• Investigational treatment for Hepatocellular Carcinoma (liver cancer).
• Investigational research for advanced solid tumors that have returned after previous treatment.
• Research into combination therapies with “Checkpoint Inhibitors” like pembrolizumab for melanoma and lung cancer.

Non-oncological uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

In clinical research settings, suratadenoturev is given as a liquid injected directly into the tumor by a specialist using ultrasound or endoscopic guidance.

Dose Adjustments

Because the drug is injected directly into a tumor and stays mostly in that area, traditional dose adjustments for renal (kidney) or hepatic (liver) insufficiency are not usually required. However, if a patient has a severe fever or a very weak immune system, the doctor may delay the next injection.

Clinical Efficacy and Research Results

Current clinical study data from 2020 to 2026 shows that suratadenoturev is highly active, especially when used with radiation.

Numerical data from Phase 1 and 2 trials in esophageal cancer showed that approximately 85 percent of patients had a “local response,” meaning the injected tumor shrank or disappeared. In some studies, research results indicated that over 50 percent of patients achieved a “complete response” when the drug was paired with standard radiation therapy. 2024 and 2025 studies are currently looking at “long-term survival rates,” with early data suggesting that the drug may help prevent the cancer from coming back in the same spot for more than 12 to 18 months.

Safety Profile and Side Effects

Black Box Warning

There is no official Black Box Warning for suratadenoturev because it is still in the investigational phase.

Common side effects

These occur in more than 10 percent of patients and are usually “flu-like” because the body is reacting to a virus:

• Fever and chills
• Pain at the injection site
• Feeling very tired (fatigue)
• Nausea
• Muscle aches

Serious adverse events

• Significant inflammation in the area of the tumor.
• Potential for a “Cytokine Storm” (a severe immune overreaction).
• Temporary decrease in white blood cell counts.
• Rare allergic reactions to the viral proteins.

Management strategies

Most side effects are managed with standard fever-reducing medicines like acetaminophen. Doctors monitor the injection site for swelling. If a patient develops a very high fever that does not go away, steroids may be used to calm the immune system.

Research Areas

Suratadenoturev is a major focus in Research Areas involving “Viral Immunotherapy.” Scientists are studying if the drug can be used alongside stem cell therapies to help deliver the virus more deeply into hidden tumors. There is also active research in regenerative medicine looking at how the body repairs healthy tissue after the virus has cleared out the cancer. Currently, the most active 2025 research is looking at “Telomelysin” in combination with modern PD-1 immunotherapies to see if the virus can make the immunotherapy work in tumors that were previously resistant.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Imaging (CT or PET scan) to measure the size of the tumor.
• Blood tests to check the baseline immune system and liver function.
• Test for pre-existing adenovirus antibodies (though this does not always prevent treatment).

Precautions during treatment

Patients should be aware that they might feel like they have a “bad cold” for 24 to 48 hours after each injection. It is important to avoid close contact with very young infants or people with severely broken immune systems for a few days after injection, as a precaution.

Do’s and Don’ts list

• Do stay well-hydrated before and after your injection.
• Do tell your doctor immediately if you have a fever higher than 101 degrees Fahrenheit.
• Do keep the injection site clean and covered as directed.
• Don’t take extra anti-inflammatory drugs like ibuprofen unless your doctor says it is okay, as these might dampen the drug’s effect.
• Don’t ignore sudden, severe pain or swelling in the treated area.
• Don’t miss your follow-up scans, as these track if the “Smart Drug” is working.

Legal Disclaimer

The information provided in this guide is for informational purposes only and does not constitute medical advice. Suratadenoturev is an investigational drug and is not approved by the Food and Drug Administration (FDA) for general use outside of clinical trials. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment.